Arvinas (ARVN) closed at $7.86 on October 30, 2026, down 0.5% from the previous close, on volume of 1,081,558 shares (30-day average 722,199).
Data as of October 30, 2026.
30-Oct-2026
Globe Newswire (Tue, 27-Oct 4:01 PM ET)
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
Globe Newswire (Tue, 27-Oct 7:00 AM ET)
Globe Newswire (Wed, 7-Oct 7:00 AM ET)
Globe Newswire (Thu, 1-Oct 4:01 PM ET)
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 29-Sep 4:01 PM ET)
Globe Newswire (Mon, 28-Sep 7:00 AM ET)
Arvinas to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 3-Sep 4:06 PM ET)
Market Chameleon (Tue, 4-Aug 7:18 AM ET)
Market Chameleon (Tue, 4-Aug 4:29 AM ET)
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Tue, 4-Aug 7:00 AM ET)
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Arvinas trades on the NASDAQ stock market under the symbol ARVN.
As of October 30, 2026, ARVN stock price declined to $7.86 with 1,081,558 million shares trading.
ARVN has a beta of 1.51, meaning it tends to be more sensitive to market movements. ARVN has a correlation of 0.16 to the broad based SPY ETF.
ARVN has a market cap of $513.94 million. This is considered a Small Cap stock.
Last quarter Arvinas reported $250 million in Revenue and $2.58 earnings per share. This beat revenue expectation by $193 million and exceeded earnings estimates by $2.84.
In the last 3 years, ARVN traded as high as $53.08 and as low as $5.90.
The top ETF exchange traded funds that ARVN belongs to (by Net Assets): VTI, IWM, VXF, IWN, FESM.
ARVN has underperformed the market in the last year with a return of -20.8%, while the SPY ETF gained +12.3%. In the last 3 month period, ARVN fell short of the market, returning -5.3%, while SPY returned +2.1%. However, in the most recent 2 weeks ARVN has outperformed the stock market by returning +12.8%, while SPY returned -1.0%.
ARVN support price is $7.64 and resistance is $8.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARVN shares will trade within this expected range on the day.